Seelos Therapeutics Announces Amendment of SLS-002 Agreement
2019年10月21日 - 10:00PM
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company, today announced an amendment of the
agreement with Vyera Pharmaceuticals for the development of
SLS-002. This amendment now removes the requirement to conduct a
Phase III trial and converts the one-time cash payment obligation
otherwise owed to Vyera for commencement of the Phase III trial to
a series a cash and stock payments over the next 9 months. Based on
feedback from its Type C meeting with FDA, Seelos plans to conduct
a Phase II Proof of Concept (PoC) trial in Suicidality in Major
Depressive Disorder (MDD). “Amending this agreement for the
development of SLS-002 allows us to proceed with our plans to
conduct a Proof of Concept study to evaluate the safety,
tolerability, and efficacy of SLS-002, as well as exploring the
validation of the Sheehan Suicidality Tracking Scale in this
population,” said Raj Mehra, Chairman and CEO of Seelos.
“Initiating this study in MDD will allow us to pursue development
in targeting a huge unmet clinical need as well as potentially
provide for a larger market opportunity than PTSD which we also
plan to pursue.” About Seelos Therapeutics: Seelos Therapeutics,
Inc. is a clinical-stage biopharmaceutical company focused on the
development and advancement of novel therapeutics to address unmet
medical needs for the benefit of patients with central nervous
system (CNS) disorders and other rare disorders. The Company's
robust portfolio includes several late-stage clinical assets
targeting psychiatric and movement disorders, including orphan
diseases. Seelos is based in New York, New York. For more
information, please visit our
website: http://seelostherapeutics.com, the content of which
is not incorporated herein by reference. Forward-Looking
Statements: Statements made in this press release, which are not
historical in nature, constitute forward-looking statements for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. These statements include, among
others, those regarding our estimates of the impact of the
amendment of our agreement with Vyera Pharmaceuticals and our plans
to conduct a Phase II Proof of Concept (PoC) trial in Suicidality
in Major Depressive Disorder (MDD). These statements are based on
the company's current expectations and beliefs and are subject to a
number of factors and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Risks associated to Seelos' business include, but are
not limited to, the risk of not successfully executing its
preclinical and clinical studies, including for SLS-002, and not
gaining marketing approvals for our product candidates, the risks
associated with the implementation of a new business strategy, the
risks related to raising capital to fund our development plans and
ongoing operations, as well as other factors expressed in Seelos'
periodic filings with the U.S. Securities and Exchange Commission,
including its Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q. Although we believe that the expectations reflected
in our forward-looking statements are reasonable, we do not know
whether our expectations will prove correct. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof, even if subsequently made
available by us on our website or otherwise. We do not undertake
any obligation to update, amend or clarify these forward-looking
statements, whether as a result of new information, future events
or otherwise, except as may be required under applicable securities
laws. Contact Information: Anthony Marciano Head of Corporate
Communications Seelos Therapeutics, Inc. (Nasdaq: SEEL) 300 Park
Ave., 12th Fl New York, NY 10022 (646) 293-2136
anthony.marciano@seelostx.comhttps://seelostherapeutics.com/https://twitter.com/seelostxhttps://www.linkedin.com/company/seelos
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 9 2024 まで 10 2024
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 10 2023 まで 10 2024